Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Datamonitor Reports | Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard

Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard

While drug eluting stents have been successful in reducing the rate of restenosis following percutaneous coronary intervention, there have been safety scares over a new problem: “in-stent thrombosis”. Opinion leaders are divided over the gravity of this problem, but positive safety data are required to restore physician confidence in drug eluting stents.

Review of the acute coronary syndromes (ACS) – the indication that drives the PCI market.

Opinion leader commentary on guideline developments and key clinical trials.

Review of the key drug classes used in conjunction with PCI and the current opinion on facilitated PCI.

Opinion leader discussion of currently marketed stents, key clinical trials in stents, and the evolution from bare metal to drug eluting stents.

Since the introduction of PCI the procedure rate has increased dramatically making it one of the most common interventional procedures for heart disease. Use of PCI differs across the major markets, with this more aggressive revascularization strategy receiving greatest uptake in the United States, where coronary artery disease is most prevalent.

Evidence that facilitated PCI improves clinical outcomes remains inconclusive, although opinion leaders consider the premature interruption of ASSENT-4 to advise against facilitation with thrombolytics; the ACC/AHA guidelines suggest facilitation only in “high risk” patients, whereas the ESC say they find no evidence to recommend it at all.

While drug eluting stents have been successful in reducing restenosis rates from 20-30% to single digits, there have been safety scares over a new problem: “in-stent thrombosis”. Cordis’s Cypher and Boston Scientific’s Taxus have received some unfavourable press, but physicians are still enthusiastic about Abbott’s new stent, Xience.

Understand the PCI market, the driving indications and the drug classes prescribed in PCI patients.

Gain physician opinion on current treatment practice and how it might evolve.

Understand the negative publicity which has caused the robust drug eluting stent market to falter.

Publication: 39539
Library Code: DMHC2391
Type: Report
Format: PDF & SlidePack
Pages: 95

Table of Contents
Price: $3,800.00 / €2,539.92

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions